# A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

> **NCT01579279** · PHASE2 · TERMINATED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 1 (actual)

## Conditions studied

- Diabetic Neuropathic Pain

## Interventions

- **DRUG:** ABT-652 6 mg
- **DRUG:** ABT-652 12 mg
- **DRUG:** ABT-652 12 mg - 18 mg
- **DRUG:** Placebo
- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT01579279
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study Stopped
- **Last updated:** 2013-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579279, "A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT01579279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*